R1 RCM Inc. (NASDAQ:RCM – Get Free Report) has been given a consensus rating of “Hold” by the eighteen brokerages that are presently covering the stock, Marketbeat.com reports. Thirteen investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $15.41.
RCM has been the subject of several research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $19.00 price objective on shares of R1 RCM in a research report on Friday, June 28th. TD Cowen reaffirmed a “hold” rating and issued a $14.30 price objective (down from $20.00) on shares of R1 RCM in a research report on Monday, August 5th. Morgan Stanley lowered shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 8th. Robert W. Baird reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of R1 RCM in a research report on Tuesday, July 2nd. Finally, Stephens downgraded shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a report on Thursday, August 1st.
View Our Latest Stock Report on R1 RCM
Institutional Inflows and Outflows
R1 RCM Stock Performance
RCM stock opened at $14.18 on Wednesday. The firm has a market cap of $5.97 billion, a price-to-earnings ratio of -177.25 and a beta of 0.84. The firm has a 50-day simple moving average of $13.94 and a two-hundred day simple moving average of $13.01. R1 RCM has a one year low of $8.87 and a one year high of $15.26. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.84 and a current ratio of 1.84.
R1 RCM (NASDAQ:RCM – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The healthcare provider reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.03. The business had revenue of $627.90 million during the quarter, compared to analyst estimates of $633.10 million. R1 RCM had a negative net margin of 1.68% and a negative return on equity of 1.44%. The firm’s revenue was up 12.0% on a year-over-year basis. On average, equities analysts forecast that R1 RCM will post -0.24 EPS for the current fiscal year.
R1 RCM Company Profile
R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.
See Also
- Five stocks we like better than R1 RCM
- What Are the U.K. Market Holidays? How to Invest and Trade
- Why Lennar Stock Could Be the Best Play in the Housing Market
- There Are Different Types of Stock To Invest In
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Learn Technical Analysis Skills to Master the Stock Market
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.